Amneal Pharmaceuticals

Dare Bioscience (NASDAQ: DARE) Stock Quote

Follow Insider Trades Visit website
Last Trade: US$1.02 0.01 0.99
Volume: 99,894
5-Day Change: 2.63%
YTD Change: 22.89%
Market Cap: US$88.010M

Latest News From Dare Bioscience

June 1, 2023
Daré Bioscience to Participate in Two Upcoming Conferences: 2023 BIO International Convention and the Longwood Healthcare Leaders Spring 2023 MIT Conference
SAN DIEGO, June 01, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and CEO, will participate in two conferences during the week of June 5 th : BIO International Convention, being held June 5-8, 2023 at the Boston Convention and Exhibition Center in Boston, MA. Ms. Johnson will provide a corporate... Read More
May 31, 2023
Daré Bioscience Announces Availability of Publication on the Patient-Centered Concept Elicitation Study for Female Sexual Arousal Disorder in The Journal of Sexual Medicine
The Concept Elicitation Study Informed the Selection of the Primary, Secondary, and Exploratory Endpoints Included in the Phase 2b RESPOND Clinical Study Evaluating the Efficacy and Safety of Sildenafil Cream, 3.6% in Premenopausal Patients with Female Sexual Arousal Disorder Topline Data from the Exploratory Phase 2b RESPOND Study are Anticipated 2Q-2023 SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc.... Read More
May 11, 2023
Daré Bioscience Reports First Quarter 2023 Financial Results and Provides a Company Update
2023 Anticipated Milestones: Sildenafil Cream, 3.6% for Female Sexual Arousal Disorder Phase 2b Clinical Study Topline Data XACIATO™ First Commercial Sale Ovaprene Pivotal Contraceptive Efficacy Study Initiation DARE-PDM1 Phase 1 Clinical Study Topline Data Activities to support IND Submission and Clinical Study Initiation for DARE-VVA1 (Phase 2) and DARE-HRT1 (Phase 3) Conference Call and Webcast Today at 4:30 p.m. ET SAN... Read More
May 4, 2023
Daré Bioscience to Host First Quarter 2023 Financial Results and Company Update Conference Call and Webcast on May 11, 2023
SAN DIEGO, May 04, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, May 11, 2023, to review its financial results for the quarter ended March 31, 2023 and to provide a Company update. To access the conference call via phone, dial (800) 715-9871 (U.S.) or (646)... Read More
April 20, 2023
Daré Bioscience Announces Initiation of Subject Enrollment in a Phase 1 Thermography Study to Support Pharmacodynamic and Pharmacokinetic Characterization of Sildenafil Cream, 3.6%
Phase 1 Thermography Study Quantitative Data Expected to Complement Patient Reported Outcome Data Collected in the Exploratory Phase 2b RESPOND At-Home Study Topline Data for the Exploratory Phase 2b RESPOND Study Anticipated in 2Q-2023 SAN DIEGO, April 20, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, and Strategic Science & Technologies, LLC (SST), a Cambridge, MA... Read More
April 19, 2023
David Friend, Ph.D., Chief Scientific Officer of Daré Bioscience, to Present at the Global Pharma & Drug Delivery Summit 2023 to be held April 24-26, 2023 in Frankfurt, Germany
SAN DIEGO, April 19, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that the company’s Chief Scientific Officer, David Friend, Ph.D., will be presenting in the Keynote Forum of the Global Pharma & Drug Delivery Summit 2023 to be held April 24-26, 2023 in Frankfurt, Germany. Dr. Friend’s talk is scheduled from 9:00 – 9:25 AM CEST on April 24 th and is... Read More
April 18, 2023
Daré Bioscience Announces Publication of Positive Safety and Acceptability Data from Phase 1 Clinical Trial that Support the Potential of DARE-HRT1 Intravaginal Ring as a New Menopausal Hormone Therapy
Daré Plans to Advance DARE-HRT1 into Single Phase 3 Efficacy Trial for Treatment of Vasomotor Symptoms due to Menopause DARE-HRT1 has the potential to be the first FDA-approved monthly intravaginal ring delivering both estrogen and progestogen hormone therapy SAN DIEGO, April 18, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Climacteric , the... Read More
April 17, 2023
Daré Bioscience to Participate in Xpectives.Health SUMMIT Innovations in Women’s Health Business Conference
SAN DIEGO, April 17, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and CEO, will participate in a panel discussion at the Innovations in Women’s Health Business Conference, hosted by Xpectives.Health, on April 20, 2023 at Westin Copley Place, Boston, MA. Panel: What’s Hot and What’s Next in Women’s... Read More
March 30, 2023
Daré Bioscience Reports Full Year 2022 Financial Results and Provides a Company Update
Conference Call and Webcast Today at 4:30 p.m. ET 2022 Daré Key Portfolio Accomplishments: License Agreement with Organon to Commercialize XACIATO TM Ovaprene ® IDE Approval for Pivotal Contraceptive Efficacy Study Positive Phase 1/2 Data for both DARE-HRT1 and DARE-VVA1 Three Additional Portfolio Programs (DARE-PDM1, DARE-GML and grant-funded DARE-LBT) 2023 Anticipated Milestones: XACIATO™ First Commercial Sale Sildenafil... Read More
March 23, 2023
Daré Bioscience to Host Full-year 2022 Financial Results and Company Update Conference Call and Webcast on March 30, 2023
SAN DIEGO, March 23, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, March 30, 2023, to review its financial results for the year ended December 31, 2022 and to provide a Company update. To access the conference call via phone, dial (800) 715-9871 (U.S. & Canada) or... Read More
March 1, 2023
Daré Bioscience to Present at the 35th Annual Roth Conference
SAN DIEGO, March 01, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and CEO, will present at the 35 th Annual Roth Conference, being held March 12-14, 2023 in Laguna Niguel, CA. Ms. Johnson’s presentation is scheduled for Tuesday, March 14 th at 8:30 a.m. PDT. A live webcast of the presentation will... Read More
February 22, 2023
Daré Bioscience Announces Start of a Phase 1 Study for its Potential First-in-Category Treatment for Primary Dysmenorrhea, DARE-PDM1
SAN DIEGO, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced the start of a Phase 1 study evaluating its development program targeted at treating primary dysmenorrhea by delivering the active pharmaceutical ingredient diclofenac, a nonsteroidal anti-inflammatory drug (NSAID), in a novel way. Daré’s investigational product, DARE-PDM1, will deliver... Read More
February 1, 2023
Daré Bioscience to Participate in Three February Conferences
SAN DIEGO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and CEO, will participate in the following February conferences: 2023 BIO CEO & Investor Conference February 6-9, 2023, New York Marriott Marquis, New York, NY Company presentation: Tuesday, February 7 th at 3:00 p.m. EST Ms. Johnson... Read More
January 26, 2023
Daré Bioscience Announces Publication in Menopause: The Journal of The North American Menopause Society of Data from Phase 1 Trial of DARE-HRT1 that Support the Potential of DARE-HRT1 as an Effective Hormone Therapy for both Vasomotor and Vaginal...
Daré Plans to Advance DARE-HRT1 into Single Phase 3 Efficacy Trial for Treatment of Vasomotor Symptoms (VMS) due to Menopause DARE-HRT1 has the potential to be the first FDA-approved monthly intravaginal ring delivering both estrogen and progestogen hormone therapy SAN DIEGO, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced the publication of data... Read More
January 9, 2023
Daré Bioscience Announces Positive Pharmacokinetic (PK) Results from the DARE-HRT1 Phase 1 / 2 Study that Support the Potential of DARE-HRT1 as an Effective Hormone Therapy for both Vasomotor and Vaginal Symptoms of Menopause
Daré Plans to Advance DARE-HRT1 into Single Phase 3 Efficacy Trial for Treatment of Vasomotor Symptoms (VMS) due to Menopause DARE-HRT1 has the potential to be the first FDA-approved monthly intravaginal ring delivering both estrogen and progestogen hormone therapy SAN DIEGO, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced topline PK results from... Read More
December 12, 2022
Daré Bioscience Announces New Development Program, DARE-PDM1, as a Potential First-in-Category Treatment for Primary Dysmenorrhea
DARE-PDM1 Utilizes Proprietary Hydrogel Technology for Vaginal Delivery of Diclofenac, a Nonsteroidal Anti-Inflammatory; Phase 1 Study Targeted for 2023 2022 Daré Portfolio Accomplishments Include : Two Additional Portfolio Programs (DARE-GML and grant-funded DARE-LBT); License Agreement with Organon to Commercialize XACIATO ™ ; Ovaprene ® IDE Approval for Pivotal Contraceptive Efficacy Study; Positive Phase 1/2 Data for... Read More
Surmodics

COPYRIGHT ©2023 HEALTH STOCKS HUB